The Venture Codex Logo

The Venture Codex

3SBio

1st 3, 10th Road, Economic and Technological Development Zone, Shenyang, Liaoning, 110027, China

Overview

Biotechnology company developing and marketing biopharmaceutical products.

Founded

1993

Deals ยท 12mo

0

Links

WebsiteLinkedIn

Stage focus

Series A
Series B

Geographic focus

China
United States

Sector focus

Biotechnology

Investment portfolio

4rounds
NAMEDATESIZE
C Ray Therapeutics
Nov 2024Participated
$100 MSeries A
Allorion Therapeutics
Mar 2023Participated
$50 MSeries B
Verseau Therapeutics
Oct 2019Participated
$50 MOther Equity
Refuge Biotechnologies
May 2018Led
$25 MSeries B
C Ray Therapeutics
Nov 2024Participated
$100 MSeries A
Allorion Therapeutics
Mar 2023Participated
$50 MSeries B
Verseau Therapeutics
Oct 2019Participated
$50 MOther Equity
Refuge Biotechnologies
May 2018Led
$25 MSeries B
4
Items
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

3SBio: 4 funding rounds are recorded in the selected participation categories.All available history.
3SBio: 4 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Series A01
Series B11
Other Equity01

Monthly Deal Activity

3SBio: 4 deals are recorded across 102 months.All available history.
3SBio: 4 deals are recorded across 102 months. All available history
MonthDeals
May '181
Jun '180
Jul '180
Aug '180
Sep '180
Oct '180
Nov '180
Dec '180
Jan '190
Feb '190
Mar '190
Apr '190
May '190
Jun '190
Jul '190
Aug '190
Sep '190
Oct '191
Nov '190
Dec '190
Jan '200
Feb '200
Mar '200
Apr '200
May '200
Jun '200
Jul '200
Aug '200
Sep '200
Oct '200
Nov '200
Dec '200
Jan '210
Feb '210
Mar '210
Apr '210
May '210
Jun '210
Jul '210
Aug '210
Sep '210
Oct '210
Nov '210
Dec '210
Jan '220
Feb '220
Mar '220
Apr '220
May '220
Jun '220
Jul '220
Aug '220
Sep '220
Oct '220
Nov '220
Dec '220
Jan '230
Feb '230
Mar '231
Apr '230
May '230
Jun '230
Jul '230
Aug '230
Sep '230
Oct '230
Nov '230
Dec '230
Jan '240
Feb '240
Mar '240
Apr '240
May '240
Jun '240
Jul '240
Aug '240
Sep '240
Oct '240
Nov '241
Dec '240
Jan '250
Feb '250
Mar '250
Apr '250
May '250
Jun '250
Jul '250
Aug '250
Sep '250
Oct '250
Nov '250
Dec '250
Jan '260
Feb '260
Mar '260
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

3SBio: Health & Life Sciences is the largest displayed sector by deal count (4 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

3SBio: Health & Life Sciences is the largest displayed sector by deal count (4 deals). All available history
SectorDeals
Health & Life Sciences4
Space & Frontier Tech1

Deal Size Distribution

3SBio: 4 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

3SBio: 4 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M0
$5M-$10M0
$10M-$25M0
$25M-$50M1
$50M-$100M2
$100M-$250M1
$250M-$500M0
$500M-$1B0
$1B+0

Deals By Geography

3SBio: United States has the largest recorded deal count among the displayed regions (3 deals).All available history.

Top 2 of 2 regions; European countries are grouped as Europe.

3SBio: United States has the largest recorded deal count among the displayed regions (3 deals). All available history
RegionDeals
United States3
China1
3SBio: 20 co-investors are shown, with 20/20 HealthCare Partners sharing 1 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

3SBio: 20 co-investors are shown, with 20/20 HealthCare Partners sharing 1 recorded deals. All available history
Co-investorShared deals
20/20 HealthCare Partners1
3E Bioventures Capital1
Alexandria Venture Investments1
Danhua Capital1
Elikon Venture1
GL Ventures1
Hongshan Capital Group (Sequoia Capital China)1
Huaguang Wutong Fund1
INCE Capital1
InHarv Partners1
LongRiver Investments1
Ocean Pine Healthcare Fund1
Octagon Capital1
Qiming Venture Partners1
Sangel Capital1
ShangBay Capital1
Shenzhen Capital Group1
TaiLong Capital1
TF Capital1
The Mark Foundation for Cancer Research1

Investment Strategy

3SBio: Led accounts for 25% and participating for 75% of round participation.All available history.
3SBio: Led accounts for 25% and participating for 75% of round participation. All available history
CategoryDeals (count)Share (%)
Led125%
Participating375%
3SBio: Single-lead accounts for 0% and co-led for 100% of lead dynamics.All available history.
3SBio: Single-lead accounts for 0% and co-led for 100% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead00%
Co-led1100%

Team

Dr. Jing Lou

Chairman of the board of directors and Chief Executive Officer, Director /Founder